Details

Autor(en) / Beteiligte

• Colella, Fabio
• Garcia, João Pedro
• Sorbona, Marco
• Lolli, Andrea
• Antunes, Bernardo
• D'Atri, Domenico
• Barré, Florian P.Y.
• Oieni, Jacopo
• Vainieri, Maria Letizia
• Zerrillo, Luana
• Capar, Serdar
• Häckel, Sonja
• Cai, Yunpeng
• Creemers, Laura B.

Titel

Drug delivery in intervertebral disc degeneration and osteoarthritis: Selecting the optimal platform for the delivery of disease-modifying agents

Ist Teil von

• Journal of controlled release, 2020-12, Vol.328, p.985-999

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Osteoarthritis (OA) and intervertebral disc degeneration (IVDD) as major cause of chronic low back pain represent the most common degenerative joint pathologies and are leading causes of pain and disability in adults. Articular cartilage (AC) and intervertebral discs are cartilaginous tissues with a similar biochemical composition and pathophysiological aspects of degeneration. Although treatments directed at reversing these conditions are yet to be developed, many promising disease-modifying drug candidates are currently under investigation. Given the localized nature of these chronic diseases, drug delivery systems have the potential to enhance therapeutic outcomes by providing controlled and targeted release of bioactives, minimizing the number of injections needed and increasing drug concentration in the affected areas. This review provides a comprehensive overview of the currently most promising disease-modifying drugs as well as potential drug delivery systems for OA and IVDD therapy. Schematic representation of drug delivery strategies in osteoarthritis and disc degeneration. [Display omitted] •Efficacy of drugs for disc degeneration and osteoarthritis is hampered by their rapid clearance and lack of targeting•Drug delivery formulations limit systemic exposure, increase local bioavailability and allow for targeting strategies•Strategies to extend joint and disc residence time of drugs include the use of microparticles, nanoparticles and hydrogels•The choice of the ideal platform will vary according to the final application, desired residence time and target cell/tissue